Teva files Form 144 to sell 14,150 shares

Teva Pharmaceutical Industries Limited filed a Form 144 reporting the proposed sale of 14,150 ordinary shares with an aggregate market value of $448,107.86.

Rhea-AI Filing Summary

Teva Pharmaceutical Industries Limited filed a Form 144 reporting the proposed sale of 14,150 ordinary shares with an aggregate market value of $448,107.86. The shares are tied to a Restricted Share Unit Award with vesting/acquisition noted 03/05/2025, and the filing shows a transaction date of 03/05/2026, handled through Citigroup Global Markets.

Insights

Securities Compliance Analyst

Routine resale filing: 14,150 shares listed for sale; transaction documented via Citigroup.

The filing lists 14,150 ordinary shares and an aggregate market value of $448,107.86, and identifies the shares as arising from a Restricted Share Unit Award with vesting/acquisition dated 03/05/2025. The broker-dealer shown is Citigroup Global Markets.

As a routine Section 144 notice tied to compensation vesting, this is a disclosure of intent to sell rather than evidence of completed market activity; timing and actual sale proceeds are not provided in the excerpt.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does TEVA's Form 144 report?

The Form 144 reports a proposed sale of 14,150 ordinary shares tied to a restricted share award. It lists an aggregate market value of $448,107.86 and names Citigroup Global Markets as the broker-dealer handling the transaction.

When were the shares acquired for TEVA's Form 144 filing?

The filing links the shares to a Restricted Share Unit Award with vesting/acquisition dated 03/05/2025. The Form 144 itself is shown with a transaction or filing date of 03/05/2026 in the excerpt.

How many shares and what value are listed in TEVA's Form 144?

The Form 144 lists 14,150 shares with an aggregate market value of $448,107.86. Those figures appear in the securities information and correspond to the ordinary shares identified in the filing.

Who is the broker-dealer named in TEVA's Form 144?

The broker-dealer shown is Citigroup Global Markets, located at 390 Greenwich St, New York, NY, as listed in the filing excerpt. The filing indicates transactions are to be handled through that firm.

Does the Form 144 indicate the shares have already been sold?

No. The Form 144 in the excerpt documents a proposed resale of shares (a notice of intent). The filing lists the shares and value but does not state that the sale has been completed or provide sale proceeds.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/05/2026 - 05:43 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002026165
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	TEVA PHARMACEUTICAL INDUSTRIES LTD
SEC File Number	001-16174
Address of Issuer	TEVA PHARMACEUTICAL INDUSTRIES LIMITED 124 DVORA HANEVI'A ST. TEL AVIV ISRAEL 6944020
Phone	972 (3) 914-8213
Name of Person for Whose Account the Securities are To Be Sold	Jover Placid
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer
Relationship to Issuer	EXECUTIVE VP CHIEF HUMAN RESOURCES OFFICER

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
ORDINARY SHARES	CITIGROUP GLOBAL MARKETS 390 GREENWICH ST NEW YORK NY 10013	14150	448107.86	1149812898	03/05/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
ORDINARY SHARES	03/05/2025	RESTRICTED SHARE UNIT AWARD VESTING	TEVA PHARMACEUTICAL INDUSTRIES LIMITED			14150	03/05/2026	COMPENSATION

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	SECTION 3 E BASED ON ORDINARY SHARES. SALES WERE PERFORMED AS PART OF AN ESTABLISHED 10B51 PLAN ADOPTED IN AUGUST 2025
Date of Notice	03/05/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	08/10/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	CONFORMED SIGNATURE ON FILE
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)